CYTONUS THERAPEUTICS INC
Cargocytes, engineered cell-based drug carriers lacking nuclei that deliver therapeutic cargo (e.g., IL-12) to tumor microenvironments with precision homing
- Sector
- Biotech
- Headquarters
- Columbus, OH
- Founded
- 2018
- Latest Form D
- $11.7M, Nov 2023
- Total capital
- $21.3M
- Federal grants
- $6.9M
- 13 awards · 2020–2024
- Rank in peer group#323 of 514
- Private capital raised
- $14.4M
- 5 Form D · last Nov 2023
- 36 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 23 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Development of CA-IL-12 for Triple Negative Breast Cancer$894K
- Private capital raisedForm D · SEC · 5th filing$11.7M
- Federal grantHealth and Human S · Phase II · Development of CA-IL-12 for Triple Negative Breast Cancer$1.1M
- Federal grantHealth and Human S · Phase II · Development of CA-IL-12 for Triple Negative Breast Cancer$1.1M
- Private capital raisedForm D · SEC · 4th filing$15K
- Federal grantHealth and Human S · Phase I · Targeted therapeutic delivery to diseased lungs using enucleated mesenchymal stem cells$298K
- Federal grantHealth and Human S · Phase I · Targeted therapeutic delivery to diseased lungs using enucleated mesenchymal stem cells$298K
- Private capital raisedForm D · SEC · 3rd filing$2.5M
- Private capital raisedForm D · SEC · 2nd filing$100K
- Private capital raisedForm D · SEC · 1st filing$70K
Show 8 earlier federal awards
- Federal grantHealth and Human S · Phase I · Bioengineering a Novel Therapeutic Transporter that Crosses the Blood Brain Barrier to Treat Brain Disorders$325K
- Federal grantHealth and Human S · Phase I · Bioengineering a Novel Therapeutic Transporter that Crosses the Blood Brain Barrier to Treat Brain Disorders$325K
- Federal grantHealth and Human S · Phase I · Therapeutic platform to treat disease lung using enucleated mesenchymal stem cells0/01/2021$455K
- Federal grantHealth and Human S · Phase I · Therapeutic platform to treat disease lung using enucleated mesenchymal stem cells0/01/2021$455K
- Federal grantHealth and Human S · Phase I · Development of a Novel Therapeutic Transporter to Treat Metastatic Cancers$399K
- Federal grantHealth and Human S · Phase I · Development of a Novel Therapeutic Transporter to Treat Metastatic Cancers$399K
- Federal grantHealth and Human S · Phase I · Development of CA-IL-12 for Triple Negative Breast Cancer$387K
- Federal grantHealth and Human S · Phase I · Development of CA-IL-12 for Triple Negative Breast Cancer$387K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Linked publications#2 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Remo MoomiaieResearcherExecutive Officer, DirectorLinked by $910K in grants as PI
- Richard KlemkeResearcherDirectorLinked by $1.1M in grants as PI
- Christopher ThorneDirectorNamed in SEC Form D filings
- Jae AnDirectorNamed in SEC Form D filings
- Manisha NarasimhanDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 23- PendingSystems And Methods For Manufacturing Of Therapeutic CellsUSPTOApplication 18632925
- PendingCompositions And Methods For Therapeutic DeliveryUSPTOApplication 18176259
- PendingRapid Vaccine PlatformUSPTOApplication 18190838
Show all 23 patent records
- Systems And Methods For Manufacturing Of Therapeutic CellsMar 20, 2025 · Application 18632925Pending
- Compositions And Methods For Therapeutic DeliveryAug 3, 2023 · Application 18176259Pending
- Rapid Vaccine PlatformJul 13, 2023 · Application 18190838Pending
- Vaccines For Cancer TreatmentApplication 63741295Pending
- Therapeutic Compositions And Methods For Treating CancerApplication 63677991Pending
- Vaccines for Cancer TreatmentApplication 63678023Pending
- Manufacturing Systems And Methods For Cellular Therapeutic PlatformsApplication PCTUS2024024058Pending
- Manufacturing Of Therapeutic CellsApplication PCTUS2024024070Pending
- Compositions And Methods For Treating CancerApplication PCTUS2023085419Pending
- Manufacturing Of Therapeutic CellsApplication 63495697Pending
- Systems And Methods For Manufacturing Of Therapeutic CellsApplication PCTUS2022046436Pending
- Rapid Vaccine PlatformApplication 17885867Pending
- Manufacture Of TherapeuticsApplication 63325070Pending
- Compositions And Methods For Therapeutic DeliveryApplication PCTUS2022018007Pending
- Manufacture Of TherapeuticsApplication 63254920Pending
- Compositions And Methods For Therapeutic DeliveryApplication 63193949Pending
- Compositions And Methods For Therapeutic DeliveryApplication 63154591Pending
- Rapid Vaccine PlatformApplication PCTUS2021017506Pending
- Rapid Virus Vaccine PlatformApplication 63014002Pending
- Manufacturing Of Therapeutic CellsApplication 19168626Pending
- Rapid Virus Vaccine PlatformApplication 62975044Pending
- Therapeutic Compositions And Methods For Treating CancerApplication PCTUS2025040167Pending
- Vaccines For Cancer TreatmentApplication PCTUS2025040169Pending
Recent research by its founders
- A STAT3/integrin axis accelerates pancreatic cancer initiation and progression20258 cites
- S100A8/A9 innate immune signaling as a distinct mechanism driving progression of smoking-related breast cancers20256 cites
- A dataset of chronic nicotine-induced genes in breast cancer cells20252 cites
Related companies, and why
- Regenerate, Inc.Similar federal contract value in Biotech · null in contracts
- RESILIO THERAPEUTICS, LLCSimilar federal contract value in Biotech · null in contracts
- Mira Dx, Inc.Similar federal contract value in Biotech · null in contracts
- CellVax Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- IMMvention Therapeutix, Inc.Similar federal contract value in Biotech · null in contracts
- Regenimo Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .